BACKGROUND: The most common genetic change observed in adrenocortical carcinoma is loss of heterozygozity on chromosome 11q13. As genes on this chromosome may be important in the pathogenesis of adrenocortical carcinoma, we compared their expression profile between benign and malignant adrenocortical tissue. METHODS: We used the Affymetrix GeneChip (U133 plus 2.0) array in 54 adrenocortical tumors (11 carcinoma and 43 benign). Differential gene expression was defined as a twofold higher or lower gene expression level (p<0.05). Differentially expressed genes on microarray analysis were validated by real-time quantitative reverse-transcriptase polymerase chain reaction (RT-PCR). The area under the receiver operating characteristic (ROC) curve (AUC) was used to determined the diagnostic accuracy of the differently expressed genes for distinguishing benign from malignant tumors. RESULTS: We found 25 of the 314 genes on chromosome 11q13 to be differentially expressed between adrenocortical carcinoma and benign adrenocortical tumor. All 25 were downregulated in adrenocortical carcinoma by 2-fold to 4.8-fold; 21 were validated to be differentially expressed by RT-PCR (Pearson's coefficient>0.5). Six genes (SERPING1, MRPL48, TM7SF2, DDB1, NDUSF8, PRDX5) validated by RT-PCR were significantly differentially expressed between benign and malignant adrenocortical tumors (p<0.05) with an overall accuracy of 89% for SERPING1, 91% for MRPL48, 87% for TM7SF2, 88% for DDB1, 91% for NDUFS8, and 89% for PRDX5. The AUC was 0.89 for the combination of SERPING1, MRPL48, TM7SF2, DDB1, and NDUFS8. CONCLUSIONS: We have identified 25 genes located on chromosome 11q13 that are downregulated in adrenocortical carcinoma and may be candidate tumor suppressor genes. Six of these genes were good diagnostic markers for distinguishing adrenocortical carcinoma from adenoma.
BACKGROUND: The most common genetic change observed in adrenocortical carcinoma is loss of heterozygozity on chromosome 11q13. As genes on this chromosome may be important in the pathogenesis of adrenocortical carcinoma, we compared their expression profile between benign and malignant adrenocortical tissue. METHODS: We used the Affymetrix GeneChip (U133 plus 2.0) array in 54 adrenocortical tumors (11 carcinoma and 43 benign). Differential gene expression was defined as a twofold higher or lower gene expression level (p<0.05). Differentially expressed genes on microarray analysis were validated by real-time quantitative reverse-transcriptase polymerase chain reaction (RT-PCR). The area under the receiver operating characteristic (ROC) curve (AUC) was used to determined the diagnostic accuracy of the differently expressed genes for distinguishing benign from malignant tumors. RESULTS: We found 25 of the 314 genes on chromosome 11q13 to be differentially expressed between adrenocortical carcinoma and benign adrenocortical tumor. All 25 were downregulated in adrenocortical carcinoma by 2-fold to 4.8-fold; 21 were validated to be differentially expressed by RT-PCR (Pearson's coefficient>0.5). Six genes (SERPING1, MRPL48, TM7SF2, DDB1, NDUSF8, PRDX5) validated by RT-PCR were significantly differentially expressed between benign and malignant adrenocortical tumors (p<0.05) with an overall accuracy of 89% for SERPING1, 91% for MRPL48, 87% for TM7SF2, 88% for DDB1, 91% for NDUFS8, and 89% for PRDX5. The AUC was 0.89 for the combination of SERPING1, MRPL48, TM7SF2, DDB1, and NDUFS8. CONCLUSIONS: We have identified 25 genes located on chromosome 11q13 that are downregulated in adrenocortical carcinoma and may be candidate tumor suppressor genes. Six of these genes were good diagnostic markers for distinguishing adrenocortical carcinoma from adenoma.
Authors: Patrick J Bastian; Jörg Ellinger; Axel Wellmann; Nicolas Wernert; Lukas C Heukamp; Stefan C Müller; Alexander von Ruecker Journal: Clin Cancer Res Date: 2005-06-01 Impact factor: 12.531
Authors: Mayka Sanchez; Bruno Galy; Thomas Dandekar; Peter Bengert; Yevhen Vainshtein; Jens Stolte; Martina U Muckenthaler; Matthias W Hentze Journal: J Biol Chem Date: 2006-06-07 Impact factor: 5.157
Authors: C Wachenfeld; F Beuschlein; O Zwermann; P Mora; M Fassnacht; B Allolio; M Reincke Journal: Eur J Endocrinol Date: 2001-09 Impact factor: 6.664
Authors: Yong Cang; Jianxuan Zhang; Sally A Nicholas; Arianna L Kim; Pengbo Zhou; Stephen P Goff Journal: Proc Natl Acad Sci U S A Date: 2007-02-14 Impact factor: 11.205
Authors: B Skogseid; C Larsson; P G Lindgren; E Kvanta; J Rastad; E Theodorsson; L Wide; E Wilander; K Oberg Journal: J Clin Endocrinol Metab Date: 1992-07 Impact factor: 5.958
Authors: Diana Rita Szabó; Kornélia Baghy; Peter M Szabó; Adrienn Zsippai; István Marczell; Zoltán Nagy; Vivien Varga; Katalin Éder; Sára Tóth; Edit I Buzás; András Falus; Ilona Kovalszky; Attila Patócs; Károly Rácz; Peter Igaz Journal: Cell Mol Life Sci Date: 2013-06-27 Impact factor: 9.261
Authors: Adrienn Zsippai; Diana Rita Szabó; Peter M Szabó; Zsófia Tömböl; Melinda R Bendes; Zoltán Nagy; Károly Rácz; Peter Igaz Journal: Am J Cancer Res Date: 2011-04-25 Impact factor: 6.166
Authors: M S Petronek; J M Stolwijk; S D Murray; E J Steinbach; Y Zakharia; G R Buettner; D R Spitz; B G Allen Journal: Redox Biol Date: 2021-01-16 Impact factor: 10.787